Effects of paroxetine and venlafaxine XR on heart rate variability in depression

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 480-484

  Davidson, Jonathan ^a   Watkins, Lana ^a   Owens, Michael ^b   Krulewicz, Stan ^c   Connor, Kathryn ^a   Carpenter, David ^c   Krishnan, Ranga ^a   Nemeroff, Charles ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADAPTATION; ADULT; ANXIETY; ARTICLE; BREATHING; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HEART RATE VARIABILITY; HUMAN; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; RESPIRATORY SINUS ARRHYTHMIA; RR INTERVAL; SINUS ARRHYTHMIA; SUSTAINED RELEASE FORMULATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES;

EID: 25444471608     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177547.28961.03     Document Type: Article

References (32)

1. Carney RM, Freedland KE, Rich MW, et al. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med. 1993;95:23-28.
2. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. J Am Med Assoc. 1993;270:1819-1825.
3. Gorman JM, Sloan RP. Heart rate variability in depression and anxiety disorders. Am Heart J. 2000;140:77-83.
4. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry. 1998;55:580-592.
5. Carney RM, Saunders RD, Freedland KE, et al. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol. 1995;76:562-564.
6. Carney RM, Freedland KE, Stein PK, et al. Effects of depression on QT interval variability after myocardial infarction. Psychosom Med. 2003;65:177-180.
7. Yeragani VK, Pohl R, Balon R, et al. Effect of imipramine treatment on heart rate variability measures. Neuropsychobiology. 1992;26:27-32.
8. Tulen JH, Bruijn A, deMan J, et al. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine. J Clin Psychopharmacol. 1996;16:135-145.
9. Rechlin T. The effect of amitriptyline, doxepin, fluvoxamine and paroxetine treatment on heart rate variability. J Clin Psychopharmacol. 1994;14:392-395.
10. Yeragani VK, Pohl R, Balon R, et al. Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder. Depress Anxiety. 2000;11:1126-1130.
11. Tucker P, Adamson P, Miranda R Jr, et al. Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol. 1997;17:370-376.
12. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702-1710.
13. Harvey AT, Rudolph RZ, Preston S. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
14. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br Med J. 2002;325:1332-1333.
15. Whyte JM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med. 2003:369-374.
16. Bennett T, Farquhar IK, Hosking DJ, et al. Assessment of methods for estimating autonomic nervous control of the heart in patients with diabetes mellitus. Diabetes. 1978;27:1167-1174.
17. Katz A, Liberty IF, Porath A, et al. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J. 1999;138:32-38.
18. Wheeler SG, Ahroni JH, Boyko EJ. Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. Diabetes Res Clin Pract. 2002;58:131-138.
19. Grossman P, Karemaker J, Wieling W. Prediction of tonic parasympathetic cardiac control using respiratory sinus arrhythmia: the need for respiratory control. Psychophysiology. 1991;28:201-216.
20. Sheehan D, Lecrubier Y, Harnett-Sheehan K, et al. The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry. 1998;59(20):22-23.
21. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
22. Spielberger CD, Gorsuch RL, Luschene R, et al. Manual for the State-Trait Anxiety Inventory. Form Y, PaIo Alto, Calif: Consulting Psychologists Press; 1983.
23. Sheehan DV. The Anxiety Disease. New York: Bantam Books; 1983.
24. Connor KM, Davidson JRT. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18:76-82.
25. Barnett SD, Tharwani HM, Hertzberg MA, et al. Tolerability of fluoxetine in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:363-367.
26. Low PA, Opfer-Gehrking TL, Zimmerman IR, et al. Evaluation of heart rate changes: electrocardiographic versus photoplethysmographic methods. Clin Auton Res. 1997;7:65-68.
27. Welch PD. The use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short modified periodograms. IEEE Trans Audio Electroacoust. 1967;15:70-73.
28. Owens MJ, Morgan WN, Plott S. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305-1322.
29. Gupta R. Column liquid chromatographic determination of paroxetine in human serum using solid-phase extraction. J Biomed Chromatogr. 1994;661:362-365.
30. Hicks DR, Wolaniuk D, Russell A, et al. A high-performance liquid chromatographic method for the simultaneous determination of venlavaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit. 1994;16:100-107.
31. Detke MJ, Lu Y, Goldstein DJ. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
32. Carney RM, Blumenthal JA, Freedland KE, et al. Low heart rate variability partially explains the effect on post-MI mortality. Arch Intern Med. 2005;165:1486-1491.